OPRM1 Genotype

If you've got surgery coming, or you've ever noticed that a standard dose of an opioid painkiller barely touched your pain or knocked you flat, one gene is part of the story. OPRM1 (opioid receptor mu 1) holds the instructions for the docking site that morphine, oxycodone, fentanyl, and your body's own natural painkillers all act on. Small inherited differences in it change how that docking site behaves.

The effects exist, but they're modest, and they point in different directions depending on the drug and the situation. So this is a research-stage test: it won't set your dose, but it adds one fixed, lifelong fact to what your surgeon or pain doctor works from. You only ever need to run it once.

The Gene and Its Most Studied Variant

Most of the pain-relieving effect of common opioid painkillers runs through one protein on your nerve cells. Scientists call it the mu-opioid receptor. It's concentrated in brain circuits that handle pain, stress, and reward, and your own natural painkillers, like beta-endorphin, use the same receptor.

Nearly every study focuses on one variant, called A118G and also listed as rs1799971. It swaps a single letter at one spot in the gene, which changes one building block of the receptor. You carry two copies of the gene, so your result reads AA (the common version on both copies), AG (one of each), or GG (two copies of the less common version).

How common the G version is depends heavily on ancestry. It's much less common in people of African descent than in people of East Asian or European descent. Early lab experiments found that the G version of the receptor gripped beta-endorphin about three times more tightly, but later experiments didn't consistently repeat that result. Several studies instead point to fewer receptor copies reaching the cell surface.

Some reports read only A118G. Sequencing can read the whole gene, and A118G isn't the only signal worth reading. In a large European-ancestry genetic study, the strongest link between this gene and opioid addiction came from a different variant, rs9478500. It lies in a stretch of the gene that doesn't build the receptor itself, close to markers that influence how much receptor gets made.

Other variants have turned up in single studies. One, rs1323040, was tied to higher painkiller use after lung cancer surgery in Chinese patients. Another, rs510769, has been tied to cancer pain severity in one small study.

Pain Relief After Surgery

The most consistent finding is that people with the G version tend to need somewhat more opioid to control pain, especially right after an operation. A pooled analysis of 36 studies found G carriers used more painkiller than AA carriers. The gap was small, and it showed up mainly after surgery rather than in long-term pain.

Cancer pain points the same way. One pooled analysis found G carriers needed more opioid for cancer pain, and another found people with two G copies needed noticeably more in the days after cancer surgery. An earlier pooled analysis judged the evidence for higher dose needs weak and its practical value unclear.

The drug matters too. In a prospective study of 222 people with cancer pain, tapentadol and methadone seemed less affected by the G variant than hydromorphone, oxycodone, and fentanyl, likely because those two drugs also work through a second route besides this receptor. In 96 people with nerve pain from the chemotherapy drug oxaliplatin, the G variant predicted a weaker response to tramadol combined with acetaminophen.

Then there are findings that run the other way. In 101 people having colorectal cancer surgery with fentanyl, it was the AA group, not the G carriers, who had more pain in the recovery room and used more fentanyl. A 480-person cancer-pain study found no clear difference in high-dose versus low-dose opioid need by this genotype.

These results don't cancel out. They show what kind of marker this is: a small nudge whose direction depends on the drug, the dose, the type of pain, and your other genes. Cancer itself can scramble the link between genotype and pain response, and surgery type pushes harder than any single letter of DNA. So a G result is a reason to expect you might need a bit more, not a forecast of your dose.

What this means for you: if you're facing an operation, your genotype is worth telling the anesthesia team. It helps them anticipate which way you might drift, while they still dose you by how you actually respond.

Side Effects and Safety

The AA genotype showed up as the higher-risk group for side effects in the 480-person cancer-pain study. AA carriers were overrepresented among people with opioid adverse reactions, especially with oxycodone. The authors advised lower starting doses and close monitoring for reactions such as slowed breathing, especially with oxycodone or morphine.

Nausea runs both ways across studies. The pooled analysis of 36 studies found G carriers had slightly less nausea, about 4 fewer people out of 100, with no difference in vomiting. But in women having laparoscopic gynecologic surgery, the G variant raised the risk of early nausea and vomiting, and the anti-nausea drug ondansetron worked well in exactly those people.

How Opioids Feel to You

Genotype changes more than pain relief. In a controlled lab study, 100 adults with little or no prior opioid exposure received set doses of hydromorphone. People with AG or GG reported more pleasant effects, like feeling talkative and driven, and fewer unpleasant ones, like nausea, itching, and sedation.

The AA group had the more classic opioid response across doses. At the two lowest doses tested, 2 mg and 4 mg, G carriers felt less from the drug than AA carriers did.

The gene also touches your built-in pain control. In people with fibromyalgia and in healthy volunteers, G carriers had a weaker natural pain-dampening response, and the effect depended partly on a serotonin receptor gene. In women who get migraine with aura, the A118G genotype was linked to how severe their head pain was.

Addiction Risk

The popular idea is that the G version is an addiction gene. The largest study points the other way, and even there the effect is small. Results from smaller studies scatter in both directions.

Sources: Zhou et al. (2020); Schwantes-An et al. (2015); Al-Eitan et al. (2021).

Other studies add more static. A family-based study of heroin dependence found no link to A118G at all. Among 86 white men who used heroin, G carriers reported more consequences, more attempts to quit, and more treatment seeking. In African Americans, a pattern of several variants across the gene, rather than A118G alone, was linked to substance dependence.

Protective in one group, risky in another: that's what a weak signal looks like once it's filtered through ancestry, drug type, and study size. Addiction is built from many genes plus environment. In the large health-record study, common genetic variants overall explained only 11.3% of the differences in who developed opioid use disorder, and other studies keep finding new genes involved.

What this means for you: your genotype doesn't tell you whether you'll become addicted. Family history, mental health, and how opioids are prescribed to you matter far more than this one letter.

Opioid Treatment and Recovery

Genotype has also been studied in people being treated for opioid addiction. In a randomized trial of methadone and buprenorphine-naloxone, among 52 methadone-treated participants in the primary analysis, AA carriers had about five times as many urine screens free of other opioids as G carriers. A pooled analysis, though, concluded that this variant alone doesn't determine how well methadone works or what dose someone needs.

For alcohol, the story is simpler. A pooled analysis found the variant doesn't predict whether naltrexone, a medicine that blocks this receptor, helps people with alcohol use disorder cut back.

In 86 newborns exposed to opioids in the womb, babies with AG or GG went home about 8.5 days sooner and needed less treatment for withdrawal than AA babies.

What a Genotype Report Can Miss

Your DNA doesn't change with meals, medications, or time of day, so the usual lab pitfalls don't apply here. The limits are about what the test reads and how well the research fits you.

• Coverage: a single-spot result at A118G says nothing about the rest of the gene. Sequencing reads more of it than single-spot tests, which is how rarer variants and patterns across the gene get found.
• Variants of unknown meaning: sequencing can turn up a rare change nobody has studied. Treat an unknown as unknown, not as good or bad news.
• Ancestry: most of the evidence comes from people of European and East Asian descent. The G version is much rarer in people of African descent, and a finding in one population may not carry over to another.
• Consumer DNA reports: a report from a consumer DNA service may already list rs1799971. For that one common spot the call is often the same, but those reports may not read the rest of the gene or meet the quality checks used for medical records.
• Tumor sequencing: a cancer sequencing report can include changes found only in tumor tissue. Use a germline pharmacogenetic result for medication decisions.

A One-Time Result

This is a test you take once. Your genotype was set before you were born and will read the same at 30 and at 80, so repeating it adds nothing unless the lab flags a call it wasn't confident about.

There's also no routine blood marker downstream of this gene to track. The value comes from having the result on file for every surgery, injury, dental procedure, or pain prescription over the rest of your life, so it's there before anyone reaches for an opioid.

What to Do With Your Result

Start by knowing where this gene stands. The main expert group that writes gene-based prescribing guidelines has found the evidence too thin to change opioid doses based on this gene alone. Its firm guidance is for a different gene, CYP2D6. That gene controls how fast your liver converts codeine and tramadol into their active forms.

So this result works best as one piece of a set. In a small randomized trial of people with long-term pain that wasn't caused by cancer, prescribing guided by this gene plus CYP2D6 and a third pain-related gene, COMT, lowered pain scores by about a fifth (59 versus 76 on a 100-point scale), with fewer side effects and lower doses. Be wary of commercial combined risk scores built on secret formulas; they haven't been properly tested.

If your result came from consumer DNA or from a report that doesn't say exactly what was tested, confirm it with a clinical pharmacogenetic test before using it to guide a prescription.

If you're AA, tell your surgical team you may get stronger effects and more side effects, and that one study advised close watching for slowed breathing, so a cautious lower starting dose may make sense. If you carry G, tell them you may need somewhat more relief after surgery, and that tapentadol or methadone looked less affected by your variant in one cancer-pain study. Either way, the prescription decision belongs to the clinician treating your pain, informed by your result.

If addiction runs in your family, don't read a reassuring genotype as clearance or a risky one as destiny. That history carries more weight than this result, and an addiction medicine specialist is the right person to talk to if it worries you. Your parents, siblings, and children each have their own genotype, and this is a low-stakes test they can take whenever an operation or opioid prescription is coming.